logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11783931 B1

PDFFull Text
Date of Patent:
Oct. 10, 2023

Filed:

Dec. 11, 2020

Drug monitoring tool

Applicant:

Takeda Pharmaceutical Company Limited, Osaka, JP;

Inventors:

Gerald Spotts, Lexington, MA (US);

Roman Pichler, Lexington, MA (US);

Michael Nelson, Lexington, MA (US);

Assignee:

TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka, JP;

Attorney:

TROUTMAN PEPPER HAMILTON SANDERS LLP

Primary Examiner:

Hiep V Nguyen

Int. Cl.
CPC ...
G16H 20/10 (2018.01); G16C 20/30 (2019.01); G09C 5/00 (2006.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); G06N 7/01 (2023.01); G16H 10/60 (2018.01); H04L 9/06 (2006.01); G16B 50/00 (2019.01); G16B 40/00 (2019.01); G16C 20/90 (2019.01);
U.S. Cl.
CPC ...
G16H 20/10 (2018.01); G06N 7/01 (2023.01); G09C 5/00 (2013.01); G16C 20/30 (2019.02); G16H 10/60 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); H04L 9/0637 (2013.01); G16B 40/00 (2019.02); G16B 50/00 (2019.02); G16C 20/90 (2019.02);
Abstract

A drug monitoring tool comprises a data receiver and an interactive user interface. The data receiver is configured to receive a pharmacokinetic (PK) profile of a patient. The interactive user interface is configured to display, to the patient, a time-varying therapeutic plasma protein level of the patient and delineate a plurality of zones within the interactive user interface associated with the time-varying therapeutic plasma protein level. The plurality of zones includes a safe zone indicating to the patient that the time-varying therapeutic plasma protein level is within a first concentration range considered safe for physical activity and a danger zone indicating to the patient that the time-varying therapeutic plasma protein level is within a second concentration range and physical activity should be limited.

Find Patent Forward Citations

Loading…